{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:30:07Z","timestamp":1793363407711,"version":"4.5.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2021,12]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Dipeptidyl peptidase 3 (DPP3) is a cytosolic enzyme involved in the degradation of various cardiovascular and endorphin mediators. High levels of circulating DPP3 (cDPP3) indicate a high risk of organ dysfunction and mortality in cardiogenic shock patients.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The aim was to assess relationships between cDPP3 during the initial intensive care unit (ICU) stay and short-term outcome in the AdrenOSS-1, a prospective observational multinational study in twenty-four ICU centers in five countries. AdrenOSS-1 included 585 patients admitted to the ICU with severe sepsis or septic shock. The primary outcome was 28-day mortality. Secondary outcomes included organ failure as defined by\u00a0the Sequential Organ Failure Assessment (SOFA) score, organ support with focus on vasopressor\/inotropic use and need for renal replacement therapy. cDPP3 levels were measured upon admission and 24\u00a0h later.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Median [IQR] cDPP3 concentration upon admission was 26.5 [16.2\u201340.4] ng\/mL. Initial SOFA score was 7 [5\u201310], and 28-day mortality was 22%. We found marked associations between cDPP3 upon ICU admission and 28-day mortality (unadjusted standardized HR 1.8 [CI 1.6\u20132.1]; adjusted HR 1.5 [CI 1.3\u20131.8]) and between cDPP3 levels and change in renal and liver SOFA score (\n p<\/jats:italic>\n \u2009=\u20090.0077 and 0.0009, respectively). The higher the initial cDPP3 was, the greater the need for organ support and vasopressors upon admission; the longer the need for vasopressor(s), mechanical ventilation or RRT and\u00a0the higher the need for fluid load (all\n p<\/jats:italic>\n \u2009<\u20090.005). In patients with cDPP3\u2009>\u200940.4\u00a0ng\/mL upon admission, a decrease in cDPP3 below 40.4\u00a0ng\/mL after 24\u00a0h was associated with an improvement of organ function at 48\u00a0h and better 28-day outcome. By contrast, persistently elevated cDPP3 at 24\u00a0h was associated with worsening organ function and high 28-day mortality.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Admission levels and rapid changes in cDPP3 predict outcome during sepsis.<\/jats:p>\n \n Trial Registration<\/jats:italic>\n ClinicalTrials.gov, NCT02393781. Registered on March 19, 2015.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s13054-021-03471-2","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T09:12:04Z","timestamp":1613553124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study"],"prefix":"10.1186","volume":"25","author":[{"name":"AdrenOSS-1 Study Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3885-9569","authenticated-orcid":false,"given":"Alice","family":"Blet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Deniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk P. T.","family":"van Lier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feriel","family":"Azibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Wittebole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin G.","family":"Chousterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Gayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Struck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertus","family":"Beishuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Damoisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Deye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Di Somma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Dugernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Gaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Huberlant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Lascarrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haikel","family":"Oueslati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pickkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Sonneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Fran\u00e7ois","family":"Laterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"3471_CR1","first-page":"457","volume":"43","author":"SC Prajapati","year":"2016","unstructured":"Prajapati SC, Chauhan SS. Human dipeptidyl peptidase III mRNA variant I and II are expressed concurrently in multiple tumor derived cell lines and translated at comparable efficiency in vitro. MolBiol Rep. 2016;43:457\u201362.","journal-title":"MolBiol Rep"},{"issue":"68","key":"3471_CR2","first-page":"630","volume":"2016","author":"X Pang","year":"1979","unstructured":"Pang X, Shimizu A, Kurita S, Zankov DP, Takeuchi K, Yasuda-Yamahara M, et al. Novel therapeutic role for dipeptidyl peptidase III in the treatment of hypertension. Hypertens Dallas Tex. 1979;2016(68):630\u201341.","journal-title":"Hypertens Dallas Tex"},{"key":"3471_CR3","doi-asserted-by":"crossref","unstructured":"Deniau B, Rehfeld L, Santos K, Dienelt A, Azibani F, Sadoune M, et al. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. Eur J Heart Fail. 2019;","DOI":"10.1002\/ejhf.1601"},{"key":"3471_CR4","doi-asserted-by":"crossref","unstructured":"Takagi K, Blet A, Levy B, Deniau B, Azibani F, Feliot E, et al. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. Eur J Heart Fail. 2019;","DOI":"10.1002\/ejhf.1600"},{"key":"3471_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13054-020-02888-5","volume":"24","author":"F D\u00e9pret","year":"2020","unstructured":"D\u00e9pret F, Amzallag J, Pollina A, Fayolle-Pivot L, Coutrot M, Chaussard M, et al. Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients. Crit Care LondEngl. 2020;24:168.","journal-title":"Crit Care LondEngl"},{"key":"3471_CR6","doi-asserted-by":"publisher","first-page":"e0238039","DOI":"10.1371\/journal.pone.0238039","volume":"15","author":"B Deniau","year":"2020","unstructured":"Deniau B, Blet A, Santos K, VaittinadaAyar P, Genest M, K\u00e4storf M, et al. Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: a proof of concept study. PLoS ONE. 2020;15:e0238039.","journal-title":"PLoS ONE"},{"key":"3471_CR7","doi-asserted-by":"publisher","DOI":"10.1373\/jalm.2018.027995","author":"L Rehfeld","year":"2018","unstructured":"Rehfeld L, Funk E, Jha S, Macheroux P, Melander O, Bergmann A. Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples. J Appl Lab Med. 2018. https:\/\/doi.org\/10.1373\/jalm.2018.027995.","journal-title":"J Appl Lab Med"},{"key":"3471_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s13054-018-2243-2","volume":"22","author":"A Mebazaa","year":"2018","unstructured":"Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman BG, Blet A, et al. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care LondEngl. 2018;22:354.","journal-title":"Crit Care LondEngl"},{"key":"3471_CR9","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00134-003-1662-x","volume":"29","author":"MM Levy","year":"2003","unstructured":"Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM\/ESICM\/ACCP\/ATS\/SIS international sepsis definitions conference. Intensive Care Med. 2003;29:530\u20138.","journal-title":"Intensive Care Med"},{"key":"3471_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40560-016-0151-6","volume":"4","author":"A Mebazaa","year":"2016","unstructured":"Mebazaa A, Laterre PF, Russell JA, Bergmann A, Gattinoni L, Gayat E, et al. Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure. J Intensive Care. 2016;4:24.","journal-title":"J Intensive Care"},{"key":"3471_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-021-03471-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13054-021-03471-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-021-03471-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T09:21:04Z","timestamp":1613553664000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-021-03471-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3471"],"URL":"https:\/\/doi.org\/10.1186\/s13054-021-03471-2","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"22 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the local ethics committees and was conducted in accordance with Directive 2001\/20\/EC, as well as Good Clinical Practices (I.C.H. version 4 of May 1, 1996 and Decision of November 24, 2006) and the declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the manuscript and are willing to attest to their qualifications as authors, disclose potential conflicts of interest, and release copyright should the manuscript be accepted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Mebazaa reports personal fees from Orion, Servier, Otsuka, Philips, Sanofi, Adrenomed, Epygon and Fire 1 and grants and personal fees from 4TEEN4, Abbott and Sphingotec. BD and ABl were invited to meetings in Hennigsdorf by 4TEEN4 Pharmaceuticals GmbH. KS and ABe are employees of 4TEEN4 Pharmaceuticals GmbH. BC served as a member of an advisory board for Roche Diagnostic. ML reports research support from sphingotec, lecture fees from Baxter and Fresenius, consulting fees from Novartis. Other authors declared no potential conflicts of interest with respect to the research authorship and\/or publication of this article. 4TEEN4 Pharmaceuticals GmbH holds patent rights on the DPP3 biomarker and humanized antibody Procizumab. This does not alter our adherence to Critical Care Medicine policies on sharing data and materials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}